Alopecia Universalis and Chronic Graft-Versus-Host Disease Treated With Ruxolitinib

    October 2018 in “ JAMA Dermatology ”
    Michelle A Borg, Reem Shalabi, Richard Childs, Brian Wells
    Studysummary Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on europepmc.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata Dermatology and therapy · 2019
    2. Risk Factors and Characterization of Vitiligo and Alopecia Areata in Patients With Chronic Graft-Versus-Host Disease JAMA dermatology · 2014

    Related research 4

    1. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib Acta Dermato Venereologica · 2020
    2. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
    3. A Case Report of Verruca Vulgaris on Basis of Alopecia Areata Successfully Treated with Diphenylcyclopropenone International journal of trichology · 2017
    4. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016